1. Volume 44, Issue 2, Pages 283-290 (February 2006)
Virologic response and resistance to adefovir in patients with chronic hepatitis B 
Scott K. Fung, Hee Bok Chae, Robert J. Fontana, Hari Conjeevaram, Jorge Marrero, Kelly Oberhelman, Munira Hussain, Anna S.F. Lok 
Journal of Hepatology 
Volume 44, Issue 2, Pages (February 2006)
DOI: /j.jhep
Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Virologic response to adefovir. Percent of patients with reduction in HBV DNA by <3 log10, 3.1–5 log10 and >5 log10copies/ml at month 6 (shaded bars) and at month 12 (open bars) is illustrated.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
Virologic response according to initial virologic response. Patients who achieved an initial virologic response are represented by the solid line; patients who did not have an initial virologic response are represented by the dashed line.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

4. Fig. 3
Cumulative probability of adefovir resistance. The cumulative probability of adefovir resistance at months 6, 12, 18 and 24 is 0, 0, 16 and 22%, respectively. The number of patients at risk at each time point is indicated. [This figure appears in colour on the web.]
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

5. Fig. 4
Clinical course of a patient with adefovir resistance. The clinical course and response to salvage therapy for a representative patient with adefovir resistance is depicted. Antiviral treatment is indicated above the graph: lamivudine was given for >1 year previously (data not shown), adefovir was given for 21 months and entecavir therapy is ongoing. HBV polymerase gene mutations are represented in the boxed panel. The solid line represents HBV DNA levels and the dashed line ALT levels. This patient was described in a previous case series, with follow-up on entecavir of only 8 months [14]. LAM, lamivudine; ADV, adefovir; ETV, entecavir; rt, reverse transcriptase; PCR, polymerase chain reaction.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2005 European Association for the Study of the Liver Terms and Conditions